Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Gopal

Showing results (261-270 of 429) with videos related to

Pageof 43
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 27, 2018
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance TherapyAndrew J Cowan, Philip A Stevenson, Edward N Libby, et al.
Blood|November 29, 2007
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapyJohn M Pagel, Nathan Hedin, Lacey Drouet, et al.
Blood|July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Ajay K Gopal, Scott E Smith, et al.
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.
Indian Journal of Endocrinology and Metabolism|July 21, 2025
Early Universal Screening with a Combination of Fasting Plasma Glucose and Glycated Haemoglobin is the Best Community Screening Strategy for Dysglycaemia in Indian YouthAbilash Nair, Jabbar P Khadar, Jayakumari Chellama, et al.
Blood|April 19, 2012
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationAjay K Gopal, Radhakrishnan Ramchandren, Owen A O'Connor, et al.
Blood|December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphomaAjay K Gopal, Robert Chen, Scott E Smith, et al.
Global Heart|December 15, 2021
Interventions to Ensure the Continuum of Care for Hypertension During the COVID-19 Pandemic in Five Indian States-India Hypertension Control InitiativeAbhishek Kunwar, Kiran Durgad, Prabhdeep Kaur, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|November 24, 2016
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantationAndrew J Cowan, Zandra K Klippel, Philip A Stevenson, et al.
Pageof 43

Showing results (261-270 of 429) with videos related to

Sort By:
Pageof 43
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 27, 2018
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance TherapyAndrew J Cowan, Philip A Stevenson, Edward N Libby, et al.
Blood|November 29, 2007
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapyJohn M Pagel, Nathan Hedin, Lacey Drouet, et al.
Blood|July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Ajay K Gopal, Scott E Smith, et al.
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.
Indian Journal of Endocrinology and Metabolism|July 21, 2025
Early Universal Screening with a Combination of Fasting Plasma Glucose and Glycated Haemoglobin is the Best Community Screening Strategy for Dysglycaemia in Indian YouthAbilash Nair, Jabbar P Khadar, Jayakumari Chellama, et al.
Blood|April 19, 2012
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationAjay K Gopal, Radhakrishnan Ramchandren, Owen A O'Connor, et al.
Blood|December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphomaAjay K Gopal, Robert Chen, Scott E Smith, et al.
Global Heart|December 15, 2021
Interventions to Ensure the Continuum of Care for Hypertension During the COVID-19 Pandemic in Five Indian States-India Hypertension Control InitiativeAbhishek Kunwar, Kiran Durgad, Prabhdeep Kaur, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|November 24, 2016
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantationAndrew J Cowan, Zandra K Klippel, Philip A Stevenson, et al.
Pageof 43